Merck KGaA to buy cancer specialist SpringWorks
By 
Phillip Broadwith2025-05-01T09:21:00
$3.9 billion deal boosts Merck’s pipeline as it faces patent expiries
Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease therapies to its pipeline. Merck will pay $47 per share of SpringWorks, making the deal worth $3.9 billion (£2.9 billion), or $3.4 billion accounting for SpringWorks’ outstanding cash and debt.